According to the announcement, Medeze Treasury held and subscribed a total of 2.4444791 shares of Kangsheng Life Group at the end of the offer, accounting for 0.95% of the total shares. This includes the 1.75 million,200 shares (0.68%) that the company has previously held, and the 694,591 shares (0.27%) of effective acceptance shares obtained in this round of offer, far less than the required 25.6 million shares (about 10.68%).

Kang Sheng's life has attracted much attention in the past two years due to the problem of umbilical cord blood storage. In 2023, the Singapore Ministry of Health found during a surprise review that the temperature of several storage tanks under the group exceeded the safety limit, and was ordered to suspend the acceptance of new samples in November last year. After an audit, the Ministry of Health revealed that Kangsheng Life has solved key problems in many areas, and the license for umbilical cord blood storage and human tissue storage services has been approved for one year.

Medeze hopes to enter the Singapore market through this acquisition, providing services such as natural killer cell analysis and storage. Despite the failure of the acquisition plan, Medeze said it will continue to explore other ways of cooperation.

Since the announcement of the acquisition news, Kangsheng Life's stock price has doubled so far. After the acquisition offer expired, the stock price remained unchanged Thursday morning at 0.33 yuan.

Thai listed company Medeze Group earlier proposed an offer to acquire 10% of the shares of local cord blood bank company Cordlife for RMB 0.25 per share. The offer ended on June 25, and finally acquired less than 1% of the shares, and it was invalid without meeting the conditions.

This round of offer was originally announced on May 13 that the acquisition price was well below the fair value range assessed by independent financial advisers ($0.478 to $0.588). On June 12, the independent consultant publicly stated that the offer was "unfair and unreasonable" and suggested that shareholders refuse to accept it.